The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Discovery/Development of Novel Therapeutics for Eukaryotic Pathogens (R21/R33)
The purpose of this FOA is to solicit applications to support early stage translational research focused on the discovery and development of novel therapeutics against select eukaryotic pathogens.
- Letter of Intent Due Date(s): January 10, 2016
- Application Due Date(s): February 10, 2016, by 5:00 PM local time of applicant organization.
RFA-AI-15-054 Expiration Date February 11, 2016
Application budgets are limited to $275,000 in direct costs over the two-year project period, with a maximum of $200,000 in direct costs allowed in any single year. The R33 award phase is limited to $300,000 in direct costs per year.